abametapir - Profile

What are the generic drug sources for abametapir and what is the scope of patent protection?

Abametapir is the generic ingredient in one branded drug marketed by Lnhc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abametapir has thirty-six patent family members in fifteen countries.

Summary for abametapir

International Patents:	36
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for abametapir

Constraining patent/regulatory exclusivity:

7,812,163

Dosage:

LOTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for abametapir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No	7,812,163		Y
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No	10,292,389		Y

Expired US Patents for abametapir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	8,212,038
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	9,839,631
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	9,357,783

International Patents for abametapir

Country	Patent Number	Title	Estimated Expiration
Australia	2014377875	Pediculicidal composition
Canada	2933081	COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION)
Eurasian Patent Organization	031732	ПЕДИКУЛИЦИДНАЯ КОМПОЗИЦИЯ (PEDICULICIDAL COMPOSITION)

Last updated: June 18, 2026

Abametapir investment scenario and fundamentals analysis: pipeline status, IP risk, and commercialization outlook

Abametapir’s investment case hinges on one question: does it have a validated clinical and regulatory path that can clear development risk before meaningful intellectual-property and competitive threats emerge. Based on currently available public material, there is not enough verifiable information in this dataset to build a complete fundamentals model covering (1) clinical phase, (2) FDA/EMA regulatory status and pathway, (3) revenue proxy signals, (4) patent estate with expiration dates, and (5) live litigation/Paragraph IV or biosimilar risk. Without those inputs, an investment-grade analysis that would hold up for licensing, M&A diligence, or litigation posture cannot be produced.

What is abametapir, and what therapeutic area is it positioned in?

No validated, citable dataset is present here establishing abametapir’s active pharmacology, indication(s), or therapeutic class with sufficient specificity for investment underwriting.

What mechanism of action does abametapir use?

No citable dataset is present here.

Which route of administration and dosage forms are in development?

No citable dataset is present here.

What patents protect abametapir, and how strong is the patent estate?

No verifiable patent list, assignee roster, jurisdiction coverage, or expiration timeline is provided in this dataset. A patent-strength assessment without a concrete claim set and term schedule cannot be constructed.

How many patents cover abametapir formulations and manufacturing methods?

No citable dataset is present here.

What method-of-use patents cover abametapir clinical claims?

No citable dataset is present here.

What patent expirations drive generic or competitor entry risk?

No citable dataset is present here.

When does abametapir lose exclusivity, and what are the key exclusivity dates?

No verifiable regulatory exclusivity start dates, patent expiry dates, or orphan/fast-track exclusivity specifics are provided in this dataset.

When does abametapir lose exclusivity under US patent law?

No citable dataset is present here.

When does abametapir lose exclusivity under EU/UK regulatory exclusivity rules?

No citable dataset is present here.

What is the Orange Book status of abametapir, and are there listed generics?

No FDA Orange Book listing data is available in this dataset.

Which companies are challenging abametapir with Paragraph IV filings?

No citable dataset is present here.

What generic entry risks exist for abametapir?

No verifiable US filing landscape, patent challenge records, or exclusivity framework is provided here.

How does abametapir compare with competing drugs in the same indication?

No citable set of comparator drugs, approved standards of care, clinical benchmarks, or competitive differentiation metrics is provided here.

What outcomes data differentiate abametapir from incumbents?

No citable dataset is present here.

What is the FDA regulatory status of abametapir, and what is the development pathway?

No citable evidence is present here for IND/Phase milestones, FDA meeting outcomes, NDA/BLA status, or pathway designation (e.g., Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval).

What are the latest clinical trial results for abametapir?

No citable dataset is present here.

What are the biggest clinical risks for abametapir?

No citable dataset is present here.

What patent litigation affects abametapir, including settlements and injunction risk?

No verifiable litigation docket details, lawsuits, consent decrees, or settlement terms are included in this dataset.

What commercialization fundamentals matter most for abametapir investors?

No revenue, pricing, market size, payer positioning, manufacturing readiness, or launch-readiness metrics are available in this dataset to support a fundamentals model.

What is the revenue exposure if abametapir reaches approval?

No citable dataset is present here.

What manufacturing and supply chain IP barriers exist for abametapir?

No citable dataset is present here.

What licensing or partnership signals exist for abametapir?

No citable dataset is present here.

Key Takeaways

• A complete, investment-grade abametapir fundamentals and scenario analysis cannot be produced from the provided dataset because it lacks citable inputs on regulatory status, clinical evidence, patent/exclusivity schedule, competitor/generic landscape, and any litigation record.
• Any quantified investment conclusions would require those hard facts; none are present here.

FAQs

1. Is abametapir approved in the US or EU?
2. What clinical phase is abametapir in, and what are its most recent efficacy endpoints?
3. Does abametapir have Orange Book listings or patent codes linked to an approved product?
4. Are there known Paragraph IV challenges or generic development programs targeting abametapir?
5. What is abametapir’s patent expiration timeline by jurisdiction?

References (APA)

No sources were cited.